Semaglutide
Also known as: Ozempic, Wegovy, Rybelsus
GLP-1 Receptor Agonist | Weight Loss & Diabetes
Overview
Long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. Over 17,000 trial participants have demonstrated significant efficacy through appetite suppression and glycemic control. The 7-day half-life enables convenient weekly dosing.
Key benefits
- 15-20% average body weight reduction
- Established cardiovascular protection
- Convenient once-weekly dosing options
- Comprehensive safety data from extensive trials
- Flexible injectable and oral formulations
Mechanism of action
Mimics native GLP-1, binding to receptors to stimulate glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite via hypothalamic pathways.
Molecular data
- Type
- GLP-1 receptor agonist
- Half-life
- ~7 days (168 hours)
Sequence
His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly
Indications
What the research community uses this compound for, with self-reported effectiveness.
Weight Loss
Clinically Significant Weight Reduction
Most effectiveFDA-approved for chronic weight management with average 15-20% body weight loss in clinical trials.
Appetite and Craving Control
Most effectiveReduces hunger and food cravings through central nervous system GLP-1 receptor activation.
Sustained Weight Maintenance
EffectiveLong-term studies show maintained weight loss with continued treatment over 2+ years.
Diabetes
Glycemic Control
Most effectiveFDA-approved for type 2 diabetes with HbA1c reductions of 1.5-2% in clinical trials.
Cardiovascular Protection
Most effectiveProven 26% reduction in cardiovascular death, MI, or stroke in high-risk diabetes patients.
Beta Cell Preservation
EffectiveImproves insulin secretion and may preserve pancreatic beta cell function.
Metabolic
Metabolic Syndrome Improvement
EffectiveAddresses multiple components: weight, glucose, blood pressure, and lipids.
NASH/Fatty Liver
ModerateEmerging evidence for improvements in non-alcoholic fatty liver disease.
Inflammation Reduction
ModerateDecreases systemic inflammation markers independent of weight loss.
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Injectable
Pre-filled pen devices for once-weekly subcutaneous injection. Brands include Ozempic (diabetes) and Wegovy (weight loss).
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Weight Loss Initiation | 0.25mg | Weekly x 4 weeks, then increase | Subcutaneous |
| Weight Loss Maintenance | 2.4mg | Weekly (after 16-week titration) | Subcutaneous |
| Diabetes Management | 0.5-1mg | Weekly | Subcutaneous |
| Cardiovascular Protection | 0.5-1mg | Weekly | Subcutaneous |
| Tolerability-Based | 0.25-2.4mg | Weekly (individualized) | Subcutaneous |
Preparation
You will need
- Semaglutide pre-filled pen or vial
- Pen needles (if using pen device)
- Alcohol swabs
- Sharps disposal container
- Injection site rotation chart
Steps
- If using pre-filled pen, attach new needle and prime per instructions
- If using vial, draw prescribed dose with appropriate syringe
- Clean injection site with alcohol swab and let dry
- Inject subcutaneously at 90-degree angle (45-degree if lean)
- Hold for 6 seconds after injection to ensure full dose delivery
- Dispose of needle safely and rotate injection sites weekly
Work out the water volume and syringe units in the reconstitution calculator →
Oral
Rybelsus tablets use SNAC technology for enhanced absorption. Requires strict administration protocol.
| Protocol | Dose | Frequency | Route / duration |
|---|---|---|---|
| Diabetes Initiation | 3mg | Daily x 30 days | Oral (empty stomach) |
| Standard Diabetes Dose | 7mg | Once daily | Oral (empty stomach) |
| Maximum Diabetes Dose | 14mg | Once daily | Oral (empty stomach) |
Preparation
You will need
- Rybelsus tablets (3mg, 7mg, or 14mg)
- Plain water only (maximum 4 ounces/120mL)
- Timer or alarm for 30-minute wait
Steps
- Take first thing in morning on completely empty stomach
- Swallow tablet whole with no more than 4 ounces plain water
- Do not crush, chew, or split tablet
- Wait at least 30 minutes before eating, drinking, or taking other medications
- After 30 minutes, resume normal activities and meals
- Take at same time each day for consistency
Work out the water volume and syringe units in the reconstitution calculator →
Interactions
Pairwise interactions with other compounds you might be cycling — the same data behind the cycle builder's safety check.
Tirzepatide
AvoidBoth are incretin mimetics with overlapping mechanisms; concurrent use increases side effects.
Insulin
MonitorMay increase hypoglycemia risk when combined; requires blood glucose monitoring.
Sulfonylureas
MonitorIncreased hypoglycemia risk; may require sulfonylurea dose reduction.
Oral Medications
TimingDelayed gastric emptying may affect absorption of oral medications.
Cagrilintide
SynergisticCombined as CagriSema in clinical trials for enhanced weight loss efficacy.
Metformin
CompatibleCommonly used together for diabetes management with good safety profile.
BPC-157
CompatibleNo contraindications; may help with GI side effects.
Timeline
Typical week-by-week effects reported in clinical and observational data.
- Week 1-4
Mild appetite reduction, possible nausea during initial dose
- Month 2-3
Noticeable weight loss (5-10% typical), improved satiety
- Month 4-6
Continued weight loss (10-15% common), stable glucose levels
- Month 6+
Weight loss plateau possible, focus on maintenance
- Diabetes
Blood sugar improvements within 1-2 weeks
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Constipation
- Abdominal pain
Stop signs — stop and seek advice
- Severe persistent abdominal pain (possible pancreatitis)
- Persistent vomiting preventing fluid intake
- Signs of thyroid tumor (neck lump, hoarseness, trouble swallowing)
- Severe allergic reaction (rash, itching, difficulty breathing)
- Vision changes (possible diabetic retinopathy progression)
- Severe hypoglycemia (if combined with insulin/sulfonylureas)
- Kidney problems (decreased urination, swelling)
Contraindications
- Personal or family history of medullary thyroid cancer
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Pregnancy or breastfeeding
- History of pancreatitis
Monitoring
- Blood glucose levels
- Signs of pancreatitis
- Thyroid nodules
- Kidney function
Quality checks
What a legitimate product looks like, what should give pause, and what should make you stop.
Good signs
- FDA-approved branded products (Ozempic, Wegovy, Rybelsus)
- Proper refrigeration verified and not expired
- Clear, colorless to slightly yellow solution in pen/vial
Warning signs
- Compounded versions - FDA warns about untested compounded semaglutide
Stop signs — don't use
- Cloudy or discolored solution
- Particles or precipitation visible
- Non-pharmacy sources or unverified online sellers
Recent research
Newer papers and trial readouts on file for this compound, with source and date.
2025-06
ESSENCE Phase 3 MASH Trial Results
NEJM published interim results showing semaglutide 2.4mg achieved MASH resolution in 62.9% of patients with moderate-to-advanced liver fibrosis, establishing efficacy in metabolic liver disease.
2024-05
FLOW Kidney Outcomes Trial
Semaglutide reduced kidney disease progression by 24% and CV death by 29% in patients with T2DM and CKD. Trial stopped early for efficacy — first GLP-1 RA to demonstrate kidney-protective benefits.
2023-11
SELECT Cardiovascular Outcomes
Landmark trial showing 20% MACE reduction with semaglutide 2.4mg in 17,604 patients with obesity and CVD but without diabetes, expanding the cardiovascular indication beyond diabetic populations.
References
Primary literature and clinical-trial data informing this entry.
Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)
Wilding, J.P.H., et al. · New England Journal of Medicine · 2021
Participants: 1,961 adults with overweight or obesity
14.9% average weight loss vs 2.4% placebo over 68 weeks with 2.4mg weekly. 86% achieved ≥5% weight loss; 51-64% achieved ≥15% weight loss.
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT)
Lincoff, A.M., et al. · New England Journal of Medicine · 2023
Participants: 17,604 participants with overweight/obesity and CVD
20% reduction in MACE (CV death, MI, or stroke) with semaglutide 2.4mg vs placebo over mean 40 months. First GLP-1 RA to demonstrate cardiovascular benefit in non-diabetic population.
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)
Marso, S.P., et al. · New England Journal of Medicine · 2016
Participants: 3,297 patients with type 2 diabetes at high CV risk
26% reduction in MACE (HR 0.74) with semaglutide vs placebo. Established cardiovascular safety and benefit profile for semaglutide in type 2 diabetes.
Two-year effects of semaglutide in adults with overweight or obesity (STEP 5)
Garvey, W.T., et al. · Nature Medicine · 2022
Participants: 304 adults with overweight or obesity
Sustained weight loss of 15.2% at week 104 vs 2.6% placebo. 77.1% achieved ≥5% weight loss at 2 years, demonstrating long-term efficacy.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (PIONEER 6)
Husain, M., et al. · New England Journal of Medicine · 2019
Participants: 3,183 patients with type 2 diabetes at high CV risk
Oral semaglutide was noninferior to placebo for cardiovascular safety. Numerically fewer CV deaths in oral semaglutide group (0.9% vs 1.9%).
Once-Weekly Semaglutide in Adolescents with Obesity (STEP TEENS)
Weghuber, D., et al. · New England Journal of Medicine · 2022
Participants: 201 adolescents aged 12-17 years
16.1% BMI reduction with semaglutide vs 0.6% increase with placebo over 68 weeks. 44.9% of semaglutide recipients reclassified to normal-weight or overweight BMI category.
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF)
Kosiborod, M.N., et al. · New England Journal of Medicine · 2023
Participants: 529 patients with HFpEF and obesity
Semaglutide 2.4mg reduced symptoms, physical limitations, and improved exercise function in obesity-related HFpEF. Reduced inflammation and appeared to improve adverse cardiac remodeling.
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW)
Perkovic, V., et al. · New England Journal of Medicine · 2024
Participants: 3,533 patients with T2DM and CKD
24% lower risk of primary kidney outcome (kidney failure, sustained eGFR decline, or renal/CV death) with semaglutide vs placebo. 29% reduction in CV death. Trial stopped early for efficacy.
Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis (ESSENCE)
Sanyal, A.J., et al. · New England Journal of Medicine · 2025
Participants: 1,197 patients with MASH and fibrosis stage 2-3
62.9% achieved MASH resolution without fibrosis worsening vs 34.3% placebo at 72 weeks. Combined resolution and fibrosis improvement in 32.7% vs 16.1% placebo. Mean weight loss of 10.5%.
Last updated . How this page was sourced is described in the methodology.